Skip to content
  • Home
  • How We Work
    • The Impact of Autophagy in Health and Disease
    • Biophagy’s Business Model
    • Biophagy’s Proprietary Drug Development
    • Cell Watchᵀᴹ
  • Business Development
  • Background & News
  • Team
  • Contact
Previous Next

Biophagy is awarded a second NMSBA leverage grant with Sandia National Laboratories to lead a team of three companies (including Avisa Pharma and Omphalos Biosciences) towards identifying a lead autophagy stimulant in tuberculosis. The team will be working with human TB bacteria (M. tuberculosis, attenuated) and human macrophages to determine the effects of autophagy on isoniazid antibiotic enhancement and on U-TAID (proprietary antibiotic). They will also use an siRNA knockdown cell line to delineate the direct role of autophagy in compound activity and antibiotic enhancement.

By jordan|2022-03-22T20:38:18+00:00February 1, 2022|2019-announcements|0 Comments

Share This Story, Choose Your Platform!

FacebookTwitterRedditLinkedInWhatsAppTelegramTumblrPinterestVkXingEmail

About the Author: jordan

Related Posts

  • Biophagy presents “Autophagy: From Model Systems to Therapeutic Opportunities, 2/19/19, Keystone Symposium, Santa Fe, NM.

    Biophagy presents “Autophagy: From Model Systems to Therapeutic Opportunities, 2/19/19, Keystone Symposium, Santa Fe, NM.

Leave A Comment Cancel reply

Copyright 2022 | All Rights Reserved | Website Design and Development by Ingenuity Software Labs
FacebookTwitterInstagramPinterest
Page load link
Go to Top